Figure 2.
Mechanisms of action of elotuzumab. The primary mechanism of action of elotuzumab against myeloma cells is NK cell-mediated ADCC. Elotuzumab can also interfere with the adhesion of myeloma cells to BMSC, or can induce NK cell activation directly through binding CS1 expressed on NK cells.
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; BMSC, bone marrow stromal cells; NK, natural killer.